WEST HAVEN, Conn. & EMERYVILLE, Calif.--(BUSINESS WIRE)--Oct. 28, 2005--Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the selection of Nexavar(R) (sorafenib tosylate) Tablets as the global trade name for sorafenib, the oral investigational drug under FDA review for the treatment of advanced renal cell carcinoma (RCC), or kidney cancer.
